ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ALT vs AVTX // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Altimmune Inc. (NASDAQ) VS. Avalo Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ALT 6 — AVTX 1
■ METRIC PARITY
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALT VS. AVTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ALT AVTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -34.70% -35.00% +0.30 ALT /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -16.23% -12.90% -3.33 AVTX /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 105.00% -65.00% +170.00 ALT /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.30 0.66 +0.64 ALT /balance-sheet <GO>
Piotroski F-Score Quality 5/9 2/9 +3.00 ALT /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 34.5 25.3 +9.20 ALT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $416.3M $399.0M $17.3M ALT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ALT REV AVTX REV ALT GROSS % AVTX GROSS % ALT FCF AVTX FCF
FY 2025 $41.0K $59.0K — — -$67.5M -$51.5M
FY 2024 $20.0K $441.0K — — -$79.8M -$49.1M
FY 2023 $426.0K $1.9M — — -$75.8M -$30.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALT // BETA —
AVTX // BETA —